Cargando…
Beyond PD-L1—Identification of Further Potential Therapeutic Targets in Oral Cancer
SIMPLE SUMMARY: Tumor immunotherapy is rapidly evolving and approved for the treatment of advanced OSCC cases. In addition, the currently observed shift in the use of checkpoint inhibitors from palliative to neoadjuvant treatment may improve survival. However, not all patients respond to currently a...
Autores principales: | Weber, Manuel, Lutz, Rainer, Olmos, Manuel, Glajzer, Jacek, Baran, Christoph, Nobis, Christopher-Philipp, Möst, Tobias, Eckstein, Markus, Kesting, Marco, Ries, Jutta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997752/ https://www.ncbi.nlm.nih.gov/pubmed/35406584 http://dx.doi.org/10.3390/cancers14071812 |
Ejemplares similares
-
Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck – a case series and review of literature
por: Olmos, Manuel, et al.
Publicado: (2022) -
Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response
por: Olmos, Manuel, et al.
Publicado: (2021) -
The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?
por: Trumet, Leah, et al.
Publicado: (2023) -
Early MDO with a Virtually Planned Distractor in a Neonate with Pierre Robin Sequence
por: Lutz, Rainer, et al.
Publicado: (2022) -
Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia
por: Ries, Jutta, et al.
Publicado: (2021)